Resources

February 06, 2023

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.

Download

Explore more

News

Viralgen collaborates with Trogenix to advance AAV gene therapy for glioblastoma

Viralgen accelerates clinical development process: scaling manufacturing and completing GMP production of Trogenix’s AAV gene therapy in under 12 months. San Sebastián, Spain, 6 May 2025 – Viralgen, a leading contract development and manufacturing...

May 06, 2025

Insights

All In on Rare Disease Day 2025: Viralgen Event Highlights Critical Collaborations to Advance Successful Gene Therapies

“Understand that we are the only ones capable of doing this task, because we’ve cared from the very beginning, because we have the capabilities, and because we can bring all the pieces together. So don't underestimate the power of what you do in the...

Resources

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

VIRALGEN BUILDING 1

VIRALGEN BUILDING 2

WHO WE ARE

WHAT WE DO

EXPERT INSIGHTS

CAREERS

CONTACT US

Policies